

## SPECIALTY GUIDELINE MANAGEMENT

### LOQTORZI (toripalimab-tpzi)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### A. FDA-Approved Indications

1. Loqtorzi is indicated, in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC).
2. Loqtorzi is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

###### B. Compendial Use

Nasopharyngeal Carcinoma (NPC)

All other indications are considered experimental/investigational and not medically necessary.

##### II. EXCLUSIONS

Coverage will not be provided for members who have experienced disease progression while on PD-1 or PD-L1 inhibitor therapy.

##### III. CRITERIA FOR INITIAL APPROVAL

###### **Nasopharyngeal carcinoma (NPC)**

Authorization of 6 months may be granted when either of the following criteria are met:

- A. The requested medication will be used in combination with cisplatin and gemcitabine for the treatment of unresectable, metastatic or recurrent locally advanced NPC.
- B. The requested medication will be used as a single agent for treatment of recurrent, unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

##### IV. CONTINUATION OF THERAPY

Authorization of 6 months (for up to 24 months total when being used as first line therapy) may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

##### V. REFERENCES

1. Loqtorzi [package insert]. Redwood City, CA: Coherus BioSciences, Inc; October 2023.

Reference number
6237-A

2. The NCCN Drugs & Biologics Compendium 2024 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed March 6, 2024.